Xconomy

JULY 22, 2016

But there’s plenty more to dig through as well, from a shakeup at Zafgen to a few new high profile startups and a newly public gene therapy company. It’s the first partnership for Jounce, and a big one: the startup got a $225 million up front cash payment from Celgene and a $36 million equity investment.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 5, 2016

. —Gene therapy news: After investing in Bamboo Therapeutics and its Duchenne muscular dystrophy treatment earlier this year, Pfizer bought the Chapel Hill, NC-based biotech outright on Monday for $150 million up front , with potentially another $495 million later. His Chatham Therapeutics was acquired by Baxter International in 2014.

News 40

News Thousand Oaks Pricing Report 40

Xconomy

JUNE 10, 2016

—Meanwhile, check out reports here , here , and here for some of the other headlines coming out of ASCO, including progress made in cancer immunotherapy, the ups and downs from various presenting companies, and a visit from Vice President Joe Biden. Ed Silverman at STAT reported the analyst note first. .

Incubator 67

Incubator Thousand Oaks Screening Pricing 67

Xconomy

SEPTEMBER 30, 2016

—Amgen (NASDAQ: AMGN ), of Thousand Oaks, CA, and partner Novartis released positive results from the first Phase 3 trial of erenumab , one of a group of drugs being developed to prevent migraines , not just lessen their impact when they happen. . Phase 3 trials should start next year.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Xconomy

AUGUST 26, 2016

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. —Pfizer wasn’t done after scooping up Medivation.

Pricing 40

Pricing Thousand Oaks Startup Research 40